Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule
1997

Comparing Two Anti-CD7 Immunotoxins for Treating Leukaemia

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): DJ Flavell, DA Boehm, A Noss, SU Flavell

Primary Institution: The Simon Flavell Leukaemia Research Laboratory, University Department of Pathology, Southampton General Hospital

Hypothesis

Do immunotoxins with two toxin molecules per antibody perform better than those with one in treating leukaemia?

Conclusion

The 2-mer immunotoxin was more effective in vitro but did not show a significant therapeutic advantage in vivo compared to the 1-mer immunotoxin.

Supporting Evidence

  • The 2-mer immunotoxin was 5.6 times more effective than the 1-mer in inhibiting protein synthesis in vitro.
  • Both immunotoxins showed similar therapeutic outcomes in SCID mice despite the 2-mer's higher in vitro potency.
  • Log-rank analysis indicated no significant difference in survival between the two treatment groups.

Takeaway

Researchers tested two types of cancer treatments that deliver toxins to leukaemia cells. One type had two toxins and worked better in the lab, but both types worked similarly in mice.

Methodology

The study involved in vitro tests on HSB-2 leukaemia cells and in vivo tests on SCID mice injected with these cells.

Limitations

The study's findings may not fully translate to human treatments due to differences in mouse models.

Participant Demographics

SCID mice of both sexes, aged 6-10 weeks.

Statistical Information

P-Value

0.6306

Statistical Significance

p=0.6306

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication